VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD). In the trial, patients took 20 mg once daily for 28 days; treated patients fell asleep 42.5 minutes earlier versus 5.4 minutes on placebo — a 37-minute gap. The “pivotal” … Read more